StreetInsider.com News Articles

Cartesian Therapeutics Announces New Employment Inducement Grants

Fri, 02 Oct 2026 07:00:00 -0400

FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company’s common stock with an exercise price of $7.22, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018

Cartesian Therapeutics Announces New Employment Inducement Grants

Fri, 02 Oct 2026 07:00:00 -0400

H.C. Wainwright Reiterates Buy Rating on Cartesian Therapeutics (RNAC)

Wed, 30 Sep 2026 07:19:50 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Cartesian Therapeutics (NASDAQ: RNAC).

The analyst commented: "Five patients received a second six-week outpatient course a median 16.6 months after initial treatment, with Month 12 MG-ADL/MGC reductions of 6.6/15.0 points; 4/5 maintained ≥2-point MG-ADL improvement through Month 12, without cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), cytopenias, hypogammaglobulinemia or retreatment severe adverse events (SAEs). Recapturing sustained benefit supports an intermittent treatment approach in which patients experiencing symptom recurrence could receive another outpatient course without adding lymphodepletion. This extends Descartes-08’s potential utility beyond patients

Form 8-K Cartesian Therapeutics, For: Sep 29

Tue, 29 Sep 2026 07:33:00 -0400

si-local-file:///var/storage/secattach/20260929/27117456.html

Cartesian reports retreatment data for Descartes-08 in myasthenia gravis

Tue, 29 Sep 2026 07:31:12 -0400

Cartesian Therapeutics (NASDAQ: RNAC) presented retreatment data for its investigational therapy Descartes-08 in patients with generalized myasthenia gravis (MG) at the 2026 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting in Orlando, Florida.

The data, drawn from a case series of five patients in the Phase 2 portion of a clinical trial, examined outcomes following a second course of Descartes-08 treatment. Patients had a mean disease duration of 13 years and received retreatment at a median of 16.6 months after completing their initial treatment course. Retreatment consisted of six once-weekly infusions, matching the initial treatment protocol.

At 12 months following retreatment,

Cartesian reports retreatment data for Descartes-08 in myasthenia gravis

Tue, 29 Sep 2026 07:31:12 -0400

At 12 months following retreatment,

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Tue, 29 Sep 2026 07:30:00 -0400

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment

Median interval between end of initial treatment course and first retreatment infusion was 16.6 months

No new safety signals reported; safety profile consistent with previously reported data

Topline data from Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis expected in 1Q27

FREDERICK, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a

Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis

Tue, 29 Sep 2026 07:30:00 -0400

Descartes–08 demonstrated improvement in mean change from baseline in MG-ADL following initial treatment and retreatment; mean MG-ADL reduction of 6.6 points at Month 12 following retreatment

Median interval between end of initial treatment course and first retreatment infusion was 16.6 months

No new safety signals reported; safety profile consistent with previously reported data

Topline data from Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis expected in 1Q27

FREDERICK, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a

Form SCHEDULE 13G Cartesian Therapeutics, Filed by: BARCLAYS PLC

Thu, 13 Aug 2026 18:34:00 -0400

si-local-file:///var/storage/secattach/20260813/26923068.html

Form SCHEDULE 13G Cartesian Therapeutics, Filed by: BARCLAYS PLC

Thu, 13 Aug 2026 18:34:00 -0400

si-local-file:///var/storage/secattach/20260813/26923068.html

Cartesian Therapeutics Announces New Employment Inducement Grants

Fri, 07 Aug 2026 07:00:00 -0400

FREDERICK, Md., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees consisting of options to purchase an aggregate of 115,250 shares of the Company’s common stock with effective grant dates of August 3, 2026 and August 6, 2026. The Options have an exercise price equal to the closing trading price of the Company’s common stock on the Nasdaq Global Market on their respective grant dates, and will vest over a four-year

Cartesian Therapeutics Announces New Employment Inducement Grants

Fri, 07 Aug 2026 07:00:00 -0400

Cartesian Therapeutics Announces New Employment Inducement Grants

Fri, 07 Aug 2026 07:00:00 -0400

Cartesian Therapeutics Announces New Employment Inducement Grants

Fri, 07 Aug 2026 07:00:00 -0400

Cartesian Therapeutics (RNAC) Tops Q2 EPS by 134c

Thu, 06 Aug 2026 07:10:55 -0400

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.46, $1.34 better than the analyst estimate of ($0.88).

For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.

Form 10-Q Cartesian Therapeutics, For: Jun 30

Thu, 06 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26878519.html

Form 10-Q Cartesian Therapeutics, For: Jun 30

Thu, 06 Aug 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260806/26878519.html

Form 8-K Cartesian Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26878473.html

Form 8-K Cartesian Therapeutics, For: Aug 06

Thu, 06 Aug 2026 07:04:00 -0400

si-local-file:///var/storage/secattach/20260806/26878473.html

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:00:00 -0400

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) continues to advance; data expected in 1Q27, biologics license application (BLA) filing planned for mid-2027

Phase 2 TRITON trial of Descartes-08 in myositis on track with data from subset of patients expected in 1H27

Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis (JDM) continues to progress with data expected in 1H27